Inclusion Criteria:

1. Patients must have proven or suspected clinical stage I NSCLC. Clinical stage IA
(T1N0M0) patients are only allowed participation if the maxSUV of the primary tumor
is >/=10. Clinical stage IB (T2N0M0) must be by size criterion only (i.e. the tumor
must be > 3cm in size. Patients that have T2 tumors by visceral pleural involvement
only are not eligible for the study).

2. Patients must be surgical candidates for at least a lobectomy or other anatomical
resection (via either video-assisted thoracoscopic surgery, or open approach).

3. Patient must have an ECOG/Zubrod score of 0, 1 or 2.

4. Patients must not have undergone previous invasive mediastinal staging for this
cancer.

5. Patients must not have a tracheostomy.

6. Patient must have a CT of the chest and upper abdomen or an FDG-PET scan performed
within 60 days of enrollment to the study that confirms their clinical stage I
status. Both scans must be performed, only one needs to be within 60 days of
enrollment to the study.

Exclusion Criteria:

There are no separately noted exclusion criteria. All criteria are listed under inclusion.